accumulation of iron within neurons is toxic, leading to the observed neuronal death in in vivo and in vitro model systems of Parkinson's disease and perhaps in people with Parkinson's disease ( Fig. 1) . Whereas the data investigating the mechanism underlying toxic iron accumulation in tau-knockout neurons are intriguing, it remains to be determined whether this mechanism translates to dopaminergic neurons, as iron accumulation has been observed in these neurons in humans with Parkinson's disease 7 , and whether differences in cortical and dopaminergic neurons may enhance or attenuate APP retention in the endoplasmic reticulum.
Given the potential neurotoxic effect of iron retention in Parkinson's disease, Lei et al. 7 administered the moderate iron chelator clioquinol to tau-deficient mice to test the potential therapeutic effect of this drug. The authors found that administration of clioquinol prevents the onset of both motor dysfunction and cognitive decline in tau-deficient mice. Thus, clioquinol may represent a potential neurotherapeutic for the treatment of neurodegenerative disorders with reduced soluble tau and impaired iron export. Notably, liver iron levels as well as zinc and copper levels were not altered by treatment with clioquinol. The importance of this finding lies in the fact that this iron chelator seems to specifically target iron in the substantia nigra without producing other potentially untoward side effects. These results are interesting, as they demonstrate that clioquinol may represent an effective neurotherapeutic for the treatment of disorders with reduced soluble tau such as Parkinson's disease.
As soluble tau levels are potentially reduced in Alzheimer's disease and tauopathies and iron accumulates in these disorders 8, 10 , clioquinol treatment may be beneficial in these disorders, as well. It remains to be determined whether clioquinol can be used only as a preventative treatment in humans and might therefore only Parkinson's disease, the most common neurodegenerative movement disorder, affects more than five million people worldwide 1 . A combination of genetic and environmental factors may cause Parkinson's disease 2 . The neuropathological hallmarks of Parkinson's disease are the progressive and selective degeneration of dopaminergic neurons of the substantia nigra, a midbrain structure involved in governing movement, reward and addiction 3 , as well as the formation of Lewy bodies and Lewy neurites-intraneuronal, filamentous protein inclusions enriched in α-synuclein and ubiquitin 4 . In addition, accumulation of pathological tau in the form of neurofibrillary tangles and genome-wide association studies of the tau H1 haplotype 5 suggest that tau is also involved in Parkinson's disease pathogenesis 6 . These cellular and molecular changes in the brain ultimately result in the onset of the cardinal clinical motor features of Parkinson's disease, including rest tremor, rigidity, postural instability and bradykinesia, as well as cognitive dysfunction in advanced cases 4 .
In this issue of Nature Medicine, Lei et al. 7 provide an unexpected twist for tau in the pathogenesis of Parkinson's disease. Levels of soluble tau are reduced in the substantia nigra of individuals with Parkinson's disease, and this seems to lead to an intracellular accumulation of iron in dopaminergic neurons and a late-age nonprogressive neuronal degeneration. This occurs through inhibition of the amyloid precursor protein (APP), a neuronal ferroxidase partner for ferroportin-coupled iron export, by decreasing its surface trafficking (Fig. 1) .
The authors show that tau-deficient mice develop dopaminergic degeneration, increased iron levels, levodopa-responsive locomotor deficits and cognitive deficiencies by 12 months of age, mimicking sporadic Parkinson's disease 7 . Unlike the case in sporadic Parkinson's disease the pathologic changes do not progress in tau-deficient mice. The findings suggest that the reciprocal relationship between changes in tau levels and iron accumulation is specific to the substantia nigra, as these pathological alterations remain absent from other brain regions, including neocortex and cerebellum. Understanding how dopaminergic death occurs in tau-deficient mice with iron retention could allow for the identification and development of new therapeutics for the treatment of Parkinson's disease.
How might iron accumulate in tau-deficient neurons and lead to degeneration of dopaminergic neurons? Lei et al. 7 studied how iron is primarily exported from cortical neurons from tau-deficient mice by looking at ferroportin, a protein that interacts with APP to govern iron export 8 . Tau associates with APP and regulates its trafficking in neurons 9 . The authors found that overall levels of APP are higher in tau-deficient neurons. However, subcellular fractionation studies showed that loss of tau results in an accumulation and retention of immature APP in the endoplasmic reticulum 7 . These data suggest that tau deficiency prevents APP from being trafficked to the neuronal surface, where it matures and interacts with ferroportin to mediate iron export. The subsequent npg n e w s a n d v i e w s be beneficial for individuals who have not yet developed any clinical symptoms of the disease or whether this chelator can also be used in people with Parkinson's disease in whom the disease has already progressed. Moreover, although the use of clioquinol has been shown to be protective in rodents, it remains unclear whether the same benefits would be observed in humans or whether dangerous side effects would arise from the use of this chelator.
The model system-tau deficiency leading to neurotoxic iron retention-proposed by Lei et al. 7 is challenged by previous findings from other groups in whose experiments tau-knockout mice have a normal lifespan and do not show any substantial neurological or behavioral deficits 11 . Moreover, the absence of tau does not prevent motor deficits caused by 6-hydroxydopamine injections or overexpression of human wild-type α-synuclein in transgenic mice 12 . Given that the majority of these studies were conducted in younger mice, a careful reassessment of these models in 12-to 24-month-old mice is needed to determine and validate the contribution of tau deficiency in the neurodegeneration of dopaminergic neurons.
Although Lei et al. 7 found that soluble tau levels are selectively reduced in the substantia nigra of individuals with Parkinson's disease without a corresponding increase in the levels of insoluble tau, other studies using immunoblotting for the analyses of postmortem brain tissue from humans with Parkinson's disease found high amounts of insoluble hyperphosphorylated tau in Parkinson's disease cases 13 , even in individuals without dementia 14 . As there is no evidence that tau aggregation lowers the levels of soluble tau in vivo 11 , whether, and how, a potential decrease or loss of tau occurs in Parkinson's disease or other neurodegenerative diseases remains unknown.
One would need to presume that soluble tau that remains in Parkinson's disease may not be functioning properly, given that soluble tau is not completely absent in Parkinson's disease brains compared to the tau-knockout mice and hemizygous tau-knockout mice are normal 11 . Future studies will need to carefully evaluate the physical state of tau in Parkinson's disease to confirm that soluble tau levels are reduced and dysfunctional. This is crucial, as it has been suggested that reducing tau levels could be a potential therapy for Alzheimer's disease-related dementia 15 by normalizing network activity, reducing amyloid β toxicity and excitotoxin-related injury 11 . Thus, future tau-based therapies may require decreasing the amount of the aggregated forms of tau while maintaining the soluble form of tau.
Whereas the loss of dopaminergic neurons along with a phenotype mimicking sporadic Parkinson's disease in tau-deficient mice is interesting, it remains unclear whether Lewy bodies and Lewy neurites form in tau-deficient mice with iron retention. Moreover, it is questionable whether the observed parkinsonian symptoms and the robust loss in brain mass are solely due to the inability of neurons to maintain iron homeostasis or whether other factors may contribute to these observations. Specifically, functional consequences associated with tau loss have been stressed in a study of hippocampal cultures from tauknockout mice that showed delayed maturation of neuronal extensions in these cultures 16 . These results may suggest that the pathological changes observed by Lei et al. 7 may have additional underlying causes other than accumulation of iron.
Overall, these findings suggest the involvement of a potentially new mechanism associated with the selective loss of dopaminergic neurons in Parkinson's disease and associated parkinsonism syndromes (Fig. 1) . The finding that loss of tau interferes with iron export by preventing proper trafficking of APP to the neuronal surface, where it interacts with ferroportin, and that treatment with the moderate iron chelator clioquinol can rescue cognitive decline and iron retention suggests a therapeutic potential for clioquinol for Parkinson's disease. Future work should aim at identifying any long-term risks associated with the use of clioquinol and at uncovering whether this drug could be used as a preventative measure and be administered to people who are at risk of developing Parkinson's disease. 
